Free
Correspondence  |   May 2007
β-Blockade Abolishes Anesthetic Preconditioning: Impact on Clinical Applicability
Author Affiliations & Notes
  • Matthias L. Riess, M.D., Ph.D.
    *
  • *Medical College of Wisconsin, Milwaukee, Wisconsin.
Article Information
Correspondence
Correspondence   |   May 2007
β-Blockade Abolishes Anesthetic Preconditioning: Impact on Clinical Applicability
Anesthesiology 5 2007, Vol.106, 1061-1062. doi:10.1097/01.anes.0000265172.44877.25
Anesthesiology 5 2007, Vol.106, 1061-1062. doi:10.1097/01.anes.0000265172.44877.25
To the Editor:—
We read with interest the recent article by Dr. Lange et al.  ,1 who reported that β-blockade with esmolol abolished the cardioprotective effect of anesthetic preconditioning with 1 minimum alveolar concentration sevoflurane or desflurane but not that elicited by ischemic preconditioning in a rabbit in vivo  cardiac ischemia–reperfusion model. As interesting and important as these findings may be for the further elucidation of the signaling process involved in these powerful cardioprotective mechanisms, they certainly also add to the debate of whether anesthetic preconditioning will ever become a clinically applicable cardioprotective strategy. After all, the patients who would benefit the most from perioperative cardioprotection by volatile anesthetics are the ones who have coronary artery disease and are undergoing noncardiac or cardiac surgery, and these patients are typically on a β-blocker for perioperative cardioprotection. Together with numerous other clinical constraints, such as, age, comorbidities, timing, and dosing of the anesthetic,2 the results from this study may help to explain the unfortunate discrepancy found so far between the impressive degree of cardioprotection by volatile anesthetics in basic science research3 and the much milder results in recent clinical studies.4,5 As such, we would be interested in how the authors interpret the relevance of their findings to the clinical practice of anesthesia.
*Medical College of Wisconsin, Milwaukee, Wisconsin.
References
Lange M, Smul TM, Blomeyer CA, Redel A, Klotz KN, Roewer N, Kehl F: Role of the β1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo  . Anesthesiology 2006; 105:503–10Lange, M Smul, TM Blomeyer, CA Redel, A Klotz, KN Roewer, N Kehl, F
Riess ML, Stowe DF, Warltier DC: Cardiac pharmacological preconditioning with volatile anesthetics: From bench to bedside? Am J Physiol Heart Circ Physiol 2004; 286:H1603–7Riess, ML Stowe, DF Warltier, DC
Bienengraeber MW, Weihrauch D, Kersten JR, Pagel PS, Warltier DC: Cardioprotection by volatile anesthetics. Vasc Pharmacol 2005; 42:243–52Bienengraeber, MW Weihrauch, D Kersten, JR Pagel, PS Warltier, DC
Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, Zaugg M: Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: A double-blinded, placebo-controlled, multicenter study. Anesthesiology 2003; 98:1315–27Julier, K da Silva, R Garcia, C Bestmann, L Frascarolo, P Zollinger, A Chassot, PG Schmid, ER Turina, MI von Segesser, LK Pasch, T Spahn, DR Zaugg, M
De Hert SG, Van der Linden PJ, Cromheecke S, Meeus R, Nelis A, Van Reeth V, ten Broecke PW, De Blier IG, Stockman BA, Rodrigus IE: Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004; 101:299–310De Hert, SG Van der Linden, PJ Cromheecke, S Meeus, R Nelis, A Van Reeth, V ten Broecke, PW De Blier, IG Stockman, BA Rodrigus, IE